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Introduction . Metastatic tumors in the pancreas constitute a small (2–5%), but steadily growing percentage of all 
neoplasms of this organ. The aim of the study was to analyze the surgical treatment of metastases in the pancreas, 
in particular its effectiveness and the risk of surgical complications.
Material and methods . The retrospective analysis was performed on 21 patients treated surgically in three surgical 
centers. This group included 16 women (76%) and 5 men (24%). The median age at the time of diagnosis of the 
underlying disease was 55.5 years (41–71). We analyzed the location of secondary lesions, their size, number, type 
and radicality of surgical intervention, histopathological diagnosis of the disease, as well as the occurrence of po-
stoperative complications.
Results . The starting point for metastatic lesions in 16 patients (76%) was renal cell carcinoma (RCC), in other cases 
— skin melanoma, eyeball melanoma, adenocarcinoma of the rectum, non-small-cell bronchi carcinoma. R0 radical 
surgery was performed in 15 patients (74%) and perioperative mortality was 5% (1 patient died). The median total 
survival time was 151 months (10–342), with 168 months for RCC (25–344) and 62 months for the remaining cancers 
(10–241). 
Conclusions . The main factor that determines the patient’s future fate is the type of primary neoplasm and surgical 
treatment of metastatic tumors in the pancreas is the best solution for selected RCC cases.
NOWOTWORY J Oncol 2018; 68, 5–6: 240–244
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Introduction
The incidence of pancreatic cancer is statistically 4.8 per 
100 thousand inhabitants per year [1]. The most frequently 
diagnosed malignant cancer is adenocarcinoma, and less 
frequently neuroendocrine neoplasms. Lesions of metastatic 
nature constitute 2% to 5% of all tumors in this organ. They 
are mainly a manifestation of the propagation of malignant 
neoplasms: kidney (RCC — renal cell carcinoma), lungs, 
endocrine glands, colorectal cancer, melanoma and sarco-
mas. Almost all of these cancers have a tendency to spread 
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through the bloodstream. However, they differ in biology, 
and thus in prognosis. Thus, the decision on the form of 
therapy is important in so far as it affects the possibility 
of cure, the patient’s expected survival and quality of life 
(taking into account the risk of early complications of this 
treatment in particular).
The aim of the study is to analyze the surgical treatment 
of metastases in the pancreas, in particular taking into acco-
unt its effectiveness and the risk of surgical complications.
Material and methods
Retrospective analysis was performed on medical re-
cords of 21 patients with metastatic tumors in the pancreas, 
who were surgically treated in three surgical centers. There 
were 16 women (76%) and 5 men (24%) in this group. The 
median age at the time of diagnosis of the underlying di-
sease was 55.5 years (41–71). The diagnosis of lesions in the 
pancreas and the assessment of the possibility of their re-
moval were determined on the basis of imaging (computed 
tomography, transcutaneous ultrasound examination) and 
endoscopic examination (EUS), as well as positron emission 
tomography (PET-CT). In five cases a biopsy of lesions was 
performed, including one intraoperative biopsy, during sur-
gery performed due to other indications. The analysis spe-
cified the location of secondary lesions, their size, number 
and type of surgical intervention, as well as the occurrence 
of postoperative complications. The removed preparations 
were subjected to histopathological examination, which 
confirmed the diagnosis and legitimacy of radical surgical 
treatment. The analysis of the documentation also took 
into account: sex and age of patients, type and location 
of primary cancer, time that passed until the appearance 
of secondary lesions, including pancreatic lesions (Tab. I). 
Total survival was defined as the time from the diagnosis 
of the disease until the last observation (February 2018), 
using the Kaplan-Meier estimator. The survival time from 
the diagnosis of metastatic lesions in the pancreas was also 
evaluated in a similar way. 
Results
In the evaluated group of 21 patients in 16 (76%) the 
starting point for metastatic lesions was RCC. In other cases 
these were: skin melanoma, eyeball melanoma, adenocar-
cinoma of the rectum, non-small-cell bronchi carcinoma. In 
one person metastatic lesions of RCC to the pancreas were 
accompanied by the presence of synchronous neuroendo-
crine pancreatic tumor. The median time after which distant 
metastases appeared was 60 months (0–279), and for relap-
se in the pancreas it was 70 months (0–279) — this is presen-
ted in Table II. In two patients metastatic lesions were first 
localized in other organs (mammary gland, nasopharynx). 
In the other two — pancreatic metastatic lesions appeared 
again one year after their first occurrence in this organ. This 
led in both cases to a new surgery on the pancreas. In one 
patient, apart from a lesion in the head of the pancreas, 
the indications for surgery was massive, recurrent bleeding 
to the gastrointestinal tract. It was caused by a metastatic 
tumor infiltrating the duodenal wall. 
The total survival time in the analyzed group of patients 
was defined as the period between the diagnosis of cancer 
and death or the end of observation (February 2018) (Fig.1). 
The median total survival time was 151 months (10–342), 
with 168 months for RCC (25–344) and 62 months for the 
remaining cancers (10–241). The evaluation also included 
Table I . The study group
Parameters of the study group
Women 16 (76%)
Men 5 (24%)
Median of age 55.5 (41–71)
RCC metastases 16 (76%)
Metastases of other cancers 5 (24%)
0
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10
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Sheet = 3
21
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RCC metastases
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with metastases
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to the pancreas
Figure 1 . Survival curves for the analyzed group of patients with 
metastases to the pancreas
P = 0.004 (or the curve comparison log-rank test) 
Table II . Distribution of metastatic lesions to the pancreas by time 
interval (in months)
Months Lesions
synchronous 2 (9.5%)
0–12 3 (14%)
12–60 5 (24%)
60–120 5 (24%)
120–240 4 (19%)
> 240 2 (9.5%)
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total survival from the diagnosis of relapse in the pancreas. 
For the whole group the median total survival time was 52 
months (2–178), with 54.5 months for RCC (3–178) and 10 
months for the remaining cancers (2–52).
The size of metastatic changes in the largest dimension 
was within the range of 15–75 mm. The extent and location 
of lesions in 10 cases (47.6%) were the cause of pancreato-
splenectomy, in 8 cases (38%) — pancreatoduodenectomy, 
in 2 cases (9.5%) — clinical resection of pancreatic parenchy-
ma, in other 2 cases (9.5%) — local tumor excision, and in 1 
case (4.7%) — pancreatectomy. Detailed results of treatment 
and postoperative complications are presented in Table III.
Discussion 
The analysis of the study material and literature data 
suggest that secondary lesions in the pancreas are generally 
diagnosed accidentally in imaging performed as part of on-
cological surveillance [2]. At this stage, due to the potential 
threat and dynamics of the disease, the most important 
problem is differential diagnostics, which allows to identify 
cases of primary pancreatic adenocarcinoma. 
In order to diagnose and obtain a comprehensive picture 
of the disease, it is very important to use auxiliary tests (their 
invasiveness and time pressure resulting from the biology 
of pancreatic cancer should be considered). For this reason, 
the most important in differential diagnostics are: properly 
collected history and physical examination, imaging and 
determination of the level of cancer markers (CA 19.9, CEA, 
SCC, chromogranin A) and the evaluation of their dynamics. 
The basic examination in the diagnosis of pancreatic tumors 
is computed tomography. In its imaging, hypo- or hyperactive 
lesions, their number, regularity, pancreatic duct dilatation 
or lack of it, appearance of bile ducts, central necrosis area, 
presence of metastatic lesions in other locations or the pre-
sence of primary lesions are important. (Fig. 2, 3, 4). The above 
diagnostic measures in most cases allow us to get closer to 
the diagnosis and to exclude or confirm the presence of 
metastatic lesions in other organs. In further differentiation 
it may be useful to make EUS, PET or octreotide scan or PET 
with gallium. After ruling our primary pancreatic adenocar-
cinoma at the first stage, these tests may be helpful in esta-
blishing a management strategy [2, 3]. Final verification can 
be obtained after evaluation of the material collected during 
needle biopsy under ultrasound or during EUS examination 
(histopathological material allowing differentiation on the 
basis of immunohistochemical staining). 
The literature suggests, which is also reflected in the 
presented group of patients, that patients with pancreatic 
RCC metastases have better prognosis than other patients 
[3–7]. In the group of these patients the best prognosis is for 
those who are in good general condition (ECOG 0 or 1), have 
single or few metastases, which appeared not earlier than 
in 2 years after the disease diagnosis. Other beneficial pro-
gnostic factors [3] are: low or indirect malignancy grade in 
Fuhrman classification, radical excision of neoplastic lesions 
and lack of disease progression after systemic treatment. 
Interestingly, isolated pancreatic metastases in RCC have 
a prognosis better than similar lesions in other locations 
and may indicate an indolent course of the disease [4, 8]. 
Nevertheless, it should be noted that in our own material 
long-term survival was also observed in patients with ade-
nocarcinoma of the rectum and melanoma of the eyeball 
(8 and 5 years respectively). However, the size of the study 
group does not allow to draw general conclusions.
Table III . Outcome of surgical treatment*
Radicality  
R0 15 (74%)
R1 5 (21%)
R2 1 (5%)
Complications
DGE** 7 (30%)
pancreatic fistula 3 (13%)
other 1 (5%)
The severity of complications***
A 9 (39%)
B 1 (5%)
C 1 (5%)
Mortality******
perioperative 1 (5%)
early 1 (5%)
distant 9 (43%)
* a total of 23 surgeries due to pancreatic metastases were performed in 21 
patients 
** delayed gastric emptying (DGE)
*** according to International Study Group of Pancreatic Surgery (ISGPS) 
**** perioperative: up to 1 month after the surgery, early: 2-6 months after the 
surgery, late: more than 6 months after the surgery
Figure 2 . Hypovascular tumor of head of the pancreas — a typical 
image of adenocarcinoma
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Figure 3 . Hypervascular lesions in the pancreas — metastases of 
clear-cell carcinoma of the kidney
On the other hand, the analysis of the Italian material [7] 
shows that for patients with metastatic tumors of bronchial 
cancer, sarcomas and (in most cases) melanoma the progno-
sis is poor. Patients with secondary lesions with a starting 
point in the breast and large intestine have slightly better 
chances. It seems that apart from RCC, patients with meta-
stases of neuroendocrine tumors from other locations have 
the best prognosis. The reason for this situation is probably 
the fact that the spread of these cancers is very rarely limited, 
both in terms of the number of metastases and their loca-
tion, and the greatest benefits of the therapy are enjoyed 
by patients with beneficial biological characteristics of the 
tumor and with good response to systemic treatment [7–11]. 
Relatively good prognosis is also observed in patients with 
multi-organ resections or successive surgical treatment of 
metastatic lesions occurring over time, both in the pancreas 
and in other organs [6]. This fact was also observed in this 
paper authors’ own material. 
Researchers from the University of Leipzig have retro-
spectively analyzed 18 patients with resectional pancreatic 
metastases of different primary locations, who were surgi-
cally treated in the period of 1994–2012. The majority (n = 
10, 55.5%) were RCC metastases. Moreover, in two cases 
secondary lesions in the course of melanoma were ope-
rated on, in one case each — in the treatment of sarcoma, 
colorectal cancer, gallbladder cancer, GIST, neuroendocrine 
cancer and non-small-cell lung cancer. At the same time, 
11 patients from this group had different than pancreatic 
metastases localization with possibility of excision. For this 
reason, multiple organ resections were performed. 
The analysis carried out in this paper does not answer 
the question whether surgical treatment is clearly better 
than modern chemotherapy. The main reason for this is the 
lack of a control group. Based on literature reports, it should 
be noted that the effectiveness of modern chemotherapy 
does not differ from that of surgical treatment [12, 13]. On 
the other hand, it is worth emphasizing that in centers 
specializing in pancreatic surgery, perioperative mortality 
does not exceed 2.5–5%. Radical surgery, in particular of 
RCC metastasis (especially when it has occurred during the 
course of the disease), gives patients the chance to cure or 
survive for a long time without relapse and the feeling of the 
disease, and avoid the health and economic consequences 
of many months of palliative chemotherapy [14–20]. 
One should also not forget about other methods, espe-
cially valuable in cases of metastatic lesions being non-ope-
rable or non-resectable. Radiofrequency thermoablation, 
stereotactic radiotherapy, gamma knife or CyberKnife may 
be an effective alternative to surgical treatment in patients 
with clear contraindications to the procedure. They may also 
form part of hybrid therapy, e.g. in the case of resectional 
metastasis to the pancreas and non-resectional metastasis 
to the central nervous system [3, 20].
Conclusions
1. The main factor that determines the fate of a patient 
with metastases to the pancreas is the type of primary 
cancer. 
2. Surgical treatment of metastatic tumors in the pancreas 
is the best solution for selected RCC cases. 
3. Oncological surveillance should take into account the 
possibility of RCC metastatic lesions which are very di-
stant in time from the initial surgical treatment.
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Figure 4 . Hypervascular lesions in the pancreas — neuroendocrine 
cancer (multifocal) 
(Radiological picture of clear-cell carcinoma metastases in the pancreas and pancreatic neoplasm (multifocal) is indistinguishable)
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